Bon Natural Life (BON) Competitors

$1.27 0.00 (0.00%)

Closing price 05/22/2026 03:58 PM Eastern

Extended Trading

$1.27 0.00 (-0.31%)

As of 05/22/2026 06:25 PM Eastern

BON vs. CPHI, ATOS, INMB, HYPD, and MIRA

Should you buy Bon Natural Life stock or one of its competitors? MarketBeat compares Bon Natural Life with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bon Natural Life include China Pharma (CPHI), Atossa Genetics (ATOS), INmune Bio (INMB), Hyperion DeFi (HYPD), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry.

How does Bon Natural Life compare to China Pharma?

China Pharma (NYSE:CPHI) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

China Pharma has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market. Comparatively, Bon Natural Life has a beta of -0.19, indicating that its stock price is 119% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bon Natural Life has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. Bon Natural Life's return on equity of 0.00% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Bon Natural Life	N/A	N/A	N/A

Bon Natural Life has higher revenue and earnings than China Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.99M	7.71	-$3.08M	-$0.55	N/A
Bon Natural Life	$18.67M	0.55	-$2M	N/A	N/A

In the previous week, China Pharma had 1 more articles in the media than Bon Natural Life. MarketBeat recorded 1 mentions for China Pharma and 0 mentions for Bon Natural Life. China Pharma's average media sentiment score of 0.00 equaled Bon Natural Life'saverage media sentiment score.

Company	Overall Sentiment
China Pharma	Neutral
Bon Natural Life	Neutral

0.6% of Bon Natural Life shares are owned by institutional investors. 6.4% of China Pharma shares are owned by insiders. Comparatively, 26.5% of Bon Natural Life shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Bon Natural Life beats China Pharma on 8 of the 11 factors compared between the two stocks.

How does Bon Natural Life compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Atossa Genetics presently has a consensus target price of $36.33, suggesting a potential upside of 632.53%. Given Atossa Genetics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Atossa Genetics is more favorable than Bon Natural Life.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bon Natural Life's return on equity of 0.00% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-84.91%	-72.36%
Bon Natural Life	N/A	N/A	N/A

Atossa Genetics has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market. Comparatively, Bon Natural Life has a beta of -0.19, suggesting that its share price is 119% less volatile than the broader market.

Bon Natural Life has higher revenue and earnings than Atossa Genetics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A
Bon Natural Life	$18.67M	0.55	-$2M	N/A	N/A

In the previous week, Atossa Genetics had 3 more articles in the media than Bon Natural Life. MarketBeat recorded 3 mentions for Atossa Genetics and 0 mentions for Bon Natural Life. Bon Natural Life's average media sentiment score of 0.00 beat Atossa Genetics' score of -0.74 indicating that Bon Natural Life is being referred to more favorably in the news media.

Company	Overall Sentiment
Atossa Genetics	Negative
Bon Natural Life	Neutral

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by insiders. Comparatively, 26.5% of Bon Natural Life shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Atossa Genetics beats Bon Natural Life on 7 of the 13 factors compared between the two stocks.

How does Bon Natural Life compare to INmune Bio?

Bon Natural Life (NASDAQ:BON) and INmune Bio (NASDAQ:INMB) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

INmune Bio has a consensus price target of $8.00, suggesting a potential upside of 451.72%. Given INmune Bio's stronger consensus rating and higher possible upside, analysts plainly believe INmune Bio is more favorable than Bon Natural Life.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
INmune Bio	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17

Bon Natural Life has higher revenue and earnings than INmune Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bon Natural Life	$18.67M	0.55	-$2M	N/A	N/A
INmune Bio	$50K	770.82	-$45.93M	-$1.67	N/A

In the previous week, INmune Bio had 2 more articles in the media than Bon Natural Life. MarketBeat recorded 2 mentions for INmune Bio and 0 mentions for Bon Natural Life. INmune Bio's average media sentiment score of 0.30 beat Bon Natural Life's score of 0.00 indicating that INmune Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Bon Natural Life	Neutral
INmune Bio	Neutral

0.6% of Bon Natural Life shares are owned by institutional investors. Comparatively, 12.7% of INmune Bio shares are owned by institutional investors. 26.5% of Bon Natural Life shares are owned by company insiders. Comparatively, 21.0% of INmune Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bon Natural Life has a beta of -0.19, indicating that its share price is 119% less volatile than the broader market. Comparatively, INmune Bio has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

Bon Natural Life's return on equity of 0.00% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bon Natural Life	N/A	N/A	N/A
INmune Bio	N/A	-103.03%	-77.66%

Summary

INmune Bio beats Bon Natural Life on 9 of the 14 factors compared between the two stocks.

How does Bon Natural Life compare to Hyperion DeFi?

Bon Natural Life (NASDAQ:BON) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

Bon Natural Life's return on equity of 0.00% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bon Natural Life	N/A	N/A	N/A
Hyperion DeFi	N/A	-91.59%	-73.08%

In the previous week, Hyperion DeFi had 1 more articles in the media than Bon Natural Life. MarketBeat recorded 1 mentions for Hyperion DeFi and 0 mentions for Bon Natural Life. Hyperion DeFi's average media sentiment score of 0.54 beat Bon Natural Life's score of 0.00 indicating that Hyperion DeFi is being referred to more favorably in the news media.

Company	Overall Sentiment
Bon Natural Life	Neutral
Hyperion DeFi	Positive

0.6% of Bon Natural Life shares are held by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are held by institutional investors. 26.5% of Bon Natural Life shares are held by company insiders. Comparatively, 7.5% of Hyperion DeFi shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Bon Natural Life has higher revenue and earnings than Hyperion DeFi.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bon Natural Life	$18.67M	0.55	-$2M	N/A	N/A
Hyperion DeFi	$810K	67.75	-$45.31M	-$9.95	N/A

Bon Natural Life has a beta of -0.19, meaning that its share price is 119% less volatile than the broader market. Comparatively, Hyperion DeFi has a beta of 2.57, meaning that its share price is 157% more volatile than the broader market.

Hyperion DeFi has a consensus target price of $5.88, suggesting a potential upside of 62.29%. Given Hyperion DeFi's stronger consensus rating and higher probable upside, analysts plainly believe Hyperion DeFi is more favorable than Bon Natural Life.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

Summary

Hyperion DeFi beats Bon Natural Life on 9 of the 14 factors compared between the two stocks.

How does Bon Natural Life compare to MIRA Pharmaceuticals?

Bon Natural Life (NASDAQ:BON) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

0.6% of Bon Natural Life shares are owned by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. 26.5% of Bon Natural Life shares are owned by company insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Bon Natural Life's return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bon Natural Life	N/A	N/A	N/A
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Bon Natural Life has a beta of -0.19, indicating that its stock price is 119% less volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

Bon Natural Life has higher revenue and earnings than MIRA Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bon Natural Life	$18.67M	0.55	-$2M	N/A	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A

In the previous week, Bon Natural Life's average media sentiment score of 0.00 equaled MIRA Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Bon Natural Life	Neutral
MIRA Pharmaceuticals	Neutral

Summary

Bon Natural Life beats MIRA Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Get Bon Natural Life News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BON vs. The Competition

Export

Metric	Bon Natural Life	CONSM PD Industry	Discretionary Sector	NASDAQ Exchange
Market Cap	$10.32M	$1.43B	$7.24B	$12.34B
Dividend Yield	N/A	4.07%	2.94%	5.28%
P/E Ratio	N/A	8.81	18.52	25.66
Price / Sales	0.55	1.93	3.42	86.31
Price / Cash	N/A	14.74	14.77	56.67
Price / Book	0.18	1.38	3.71	7.14
Net Income	-$2M	$66.99M	$238.79M	$335.98M
7 Day Performance	-1.55%	0.61%	2.31%	4.11%
1 Month Performance	0.40%	-7.21%	14.65%	2.52%
1 Year Performance	-29.44%	5.17%	18.59%	35.04%

Bon Natural Life Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BON Bon Natural Life	0.7598 of 5 stars	$1.27 flat	N/A	-29.4%	$10.32M	$18.67M	N/A	100
CPHI China Pharma	N/A	$1.04 flat	N/A	-65.8%	$42.14M	$4.14M	N/A	250	News Coverage Gap Down
ATOS Atossa Genetics	2.528 of 5 stars	$4.85 flat	$36.33 +649.1%	-60.2%	$41.76M	N/A	N/A	8
INMB INmune Bio	1.398 of 5 stars	$1.55 flat	$8.00 +416.1%	-80.1%	$41.20M	$50K	N/A	10
HYPD Hyperion DeFi	3.0253 of 5 stars	$3.36 flat	$5.88 +74.9%	+104.5%	$41.06M	$810K	N/A	40	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BON) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bon Natural Life (BON) Competitors

BON vs. CPHI, ATOS, INMB, HYPD, and MIRA

How does Bon Natural Life compare to China Pharma?

Summary

How does Bon Natural Life compare to Atossa Genetics?

Summary

How does Bon Natural Life compare to INmune Bio?

Summary

How does Bon Natural Life compare to Hyperion DeFi?

Summary

How does Bon Natural Life compare to MIRA Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BON vs. The Competition

Bon Natural Life Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bon Natural Life (BON) Competitors

BON vs. CPHI, ATOS, INMB, HYPD, and MIRA

How does Bon Natural Life compare to China Pharma?

Which has more volatility and risk, CPHI or BON?

Do analysts rate CPHI or BON?

Is CPHI or BON more profitable?

Which has better earnings and valuation, CPHI or BON?

Does the media favor CPHI or BON?

Do institutionals and insiders believe in CPHI or BON?

Summary

How does Bon Natural Life compare to Atossa Genetics?

Do analysts recommend ATOS or BON?

Is ATOS or BON more profitable?

Which has more volatility & risk, ATOS or BON?

Which has preferable earnings and valuation, ATOS or BON?

Does the media favor ATOS or BON?

Do institutionals & insiders hold more shares of ATOS or BON?

Summary

How does Bon Natural Life compare to INmune Bio?

Do analysts prefer BON or INMB?

Which has better valuation & earnings, BON or INMB?

Does the media refer more to BON or INMB?

Do insiders & institutionals hold more shares of BON or INMB?

Which has more risk & volatility, BON or INMB?

Is BON or INMB more profitable?

Summary

How does Bon Natural Life compare to Hyperion DeFi?

Is BON or HYPD more profitable?

Does the media prefer BON or HYPD?

Do insiders and institutionals believe in BON or HYPD?

Which has preferable valuation & earnings, BON or HYPD?

Which has more risk & volatility, BON or HYPD?

Do analysts recommend BON or HYPD?

Summary

How does Bon Natural Life compare to MIRA Pharmaceuticals?

Do institutionals & insiders have more ownership in BON or MIRA?

Is BON or MIRA more profitable?

Do analysts prefer BON or MIRA?

Which has more risk and volatility, BON or MIRA?

Which has higher valuation & earnings, BON or MIRA?

Does the media prefer BON or MIRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BON vs. The Competition

Bon Natural Life Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools